Biotechnology company Oxford Biodynamics (OBD:AIM) has seen its shares go up three-fold in the last month driven by positive news flow.The company, which is developing precision medical tests based on its proprietary EpiSwitch3D genomics platform, announced earlier than expected validation of its prostate screening test on 26 September.The test is groundbreaking in that it has proven to be 94%...

Investors are looking hard at the stocks held in funds managed by Odey Asset Management for fear they will be dumped on the market as the hedge fund tries to raise cash. While some positions have already been cut, there remain plenty of stocks where its position has not changed (yet?).The firm is restructuring following a Financial Times investigation into alleged misconduct by founder Crispin...

Shares in biotechnology company Oxford Biodynamics (OBD:AIM) shot 23% higher to 79p on Thursday after it announced its proprietary EpiSwitch platform technology had been selected to profile COVID-19 patients.The University of Glasgow study forms part of a series of projects aimed at increasing the understanding of the coronavirus. The company, which was spun-out of Oxford University in 2007,...

Investors are cautious about buying into loss-making biotech firm Oxford BioDynamics (OBD) on its first day of trading on AIM as shares nudge a fraction to 159p.Oxford BioDynamics, which was spun-out from Oxford University in 2007, has developed a non-invasive platform called EpiSwitch. It evaluates biomarkers, which are naturally occurring molecules or genes in the body.The company's...